RCKT News and Press, Rocket Pharmaceuticals Inc. From 05/06/24

Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024 Continued preparations to launch LV portfolio beginning with KRESLADI™ (marnetegragene autotemcel) for severe LAD-I; PDUFA date of Ju...

2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...

2024-04-14 05:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-08 10:20:00 ET April 8, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech/Life Sciences sectors. The newest biotech companies are involved in preventative care...

2024-04-05 11:50:24 ET Summary Rocket Pharmaceuticals, Inc. has potential FDA approvals for its gene therapies on the horizon. The company focuses on developing gene therapies for rare diseases, targeting a market that is expected to triple in value by the end of the decade. R...

2024-04-02 14:34:13 ET Summary EMA accepted Rocket Pharmaceuticals, Inc. regulatory application of RP-L102 for the treatment of patients with Falconi Anemia. A U.S. FDA BLA filing of RP-L102 for the treatment of patients with Falconi Anemia is expected in the 1st half of 2024. ...

2024-04-02 06:55:37 ET Rocket Pharmaceuticals ( NASDAQ: RCKT ) traded higher premarket Tuesday after the EU drug regulator, the European Medicines Agency (EMA), accepted its marketing application for gene therapy candidate RP-L102 for review.... Read the full article on Se...

Positive, previously disclosed results from the global Phase 1/2 trial demonstrated genetic and phenotypic correction combined with hematologic stabilization extending out to 42 months after treatment with RP-L102 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late...

2024-03-26 16:07:33 ET More on Rocket Pharmaceuticals Rocket Pharmaceuticals' Promising Path In Gene Therapy Rocket Pharmaceuticals GAAP EPS of -$0.64 beats by $0.14 FDA extends review period for Rocket gene therapy to June 30 Seeking Alpha’s Quant Rat...

Aaron Ondrey joins as Chief Financial Officer bringing seasoned leadership experience in financial management, strategic planning, commercial finance, and capital allocation Additional key appointments within existing corporate leadership team expand capabilities and expertise spanning ea...